Publications by authors named "I Valo"
Giant cell tumors (GCTs) with high mobility group AT-Hook 2 ( HMGA2 )::nuclear receptor corepressor 2 ( NCOR2 ) fusion are rare mesenchymal tumors of controversial nosology, which have been anecdotally reported to respond to CSFR1 inhibitors. Here, we performed a comprehensive study of 6 GCTs with HMGA2::NCOR2 fusion and explored their relationship with other giant cell-rich neoplasms. Tumors occurred in 4 females and 2 males ranging in age from 17 to 32 years old (median 24).
View Article and Find Full Text PDFArticle Synopsis
- Since 2010, doctors in France have been collecting and studying cases of sarcomas and related tumors to better understand their numbers and types.
- Between 2013 and 2016, they found over 25,000 patients with different types of sarcomas, and the overall number was higher than they expected.
- The findings suggest that rare tumors are less likely to be included in clinical studies, which help create new treatments for these diseases.
Malignant mesothelioma (MM) still represents a devastating disease that is often detected too late, while the current effect of therapies on patient outcomes remains unsatisfactory. Invasiveness biomarkers may contribute to improving early diagnosis, prognosis, and treatment for patients, a task that could benefit from the development of high-throughput proteomics. To limit potential sources of bias when identifying such biomarkers, we conducted cross-species proteomic analyzes on three different MM sources.
View Article and Find Full Text PDF